(secondQuint)Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy.

 This is a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.

c.

 secukinumab 300 mg in approximately 100 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease.

 The study consists of a 4-week screening period, a 2-week run-in period, a 12-week treatment period and a 12-week follow-up period after last treatment The population will consist of patients with unilateral overuse (non-systemic inflammatory) shoulder tendinopathy, 18 - 65 years of age.

 Safety assessments will include physical examinations, ECGs, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, and urinalysis), adverse event and serious adverse event monitoring.

.

 Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy@highlight

This is a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.

c.

 secukinumab 300 mg in approximately 100 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease